-
NSD1–PPARγ Methylation in Endometrial Cancer
2026-09-21
The reference study identifies NSD1-mediated monomethylation of PPARγ at K98 as an epigenetic switch that promotes nuclear PPARγ activity, PTEN transcription, and suppression of glycolytic tumor behavior in endometrial cancer. Its rescue experiments connect this pathway to actionable metabolic biology while also defining important limits for translation into patient treatment or transcript-level workflows.
-
CHIR 99021 Trihydrochloride: Assay Design
2026-09-21
CHIR 99021 trihydrochloride is a selective GSK-3 inhibitor for linking stem-cell state, organoid composition, and metabolic phenotypes. This guide presents a decision-focused framework for using it as a tunable experimental variable rather than treating it as a universal differentiation switch.
-
A1 vs AMD3100 in Colorectal Cancer
2026-09-20
The reference study evaluates A1, a fluorinated CXCR4 inhibitor, against AMD3100 across computational, cellular, and mouse colorectal cancer models. A1 showed stronger predicted CXCR4 binding, reduced CT-26 proliferation and migration, altered immunosuppressive tumor-microenvironment signals, and improved tumor control relative to AMD3100, although substantial validation remains necessary.
-
Dimetridazole: Mechanism, Assays, and Limits
2026-09-19
Dimetridazole, also called 1,2-Dimethyl-5-nitroimidazole, is a nitroimidazole research compound for studying anaerobic bacteria, protozoa, quorum sensing, and antimicrobial combinations. Its environmental oxidation is chemically rapid under hydroxyl-radical conditions, but transformation products can retain toxicity, so assay interpretation requires both biological and analytical controls.
-
IDH2 Reprogramming and HIF-1α in Colorectal Cancer
2026-09-18
The reference study identifies IDH2 as a metabolic driver of colorectal cancer progression, linking reductive citrate-cycle activity to mitochondrial ATP production, glycolysis, and HIF-1α signaling. Its combined genetic, pharmacological, metabolic, and in vivo design provides a framework for testing whether α-ketoglutarate availability is a causal regulator rather than a passive metabolic readout.
-
Polymyxin B Sulfate in Resistance Research
2026-09-18
Polymyxin B sulfate adds a functional membrane-stress readout to workflows that already measure carbapenemase genes, plasmid transfer, and clonal spread. This guide shows how to integrate the compound into Gram-negative infection research, dendritic cell assays, and sepsis-model planning without confusing phenotypic activity with genotype-specific evidence.
-
SR-202: A Practical PPARγ Antagonist Workflow
2026-09-17
Use SR-202 to separate PPARγ-dependent transcription from downstream metabolic and inflammatory effects in adipocyte and macrophage models. This workflow translates recent PPARγ/STAT pathway findings into practical assay design, controls, and troubleshooting for insulin resistance research, obesity research, and type 2 diabetes research.
-
Tunable Human Intestinal Organoids and GSK-3 Control
2026-09-17
This Nature Communications study develops a small-molecule strategy for maintaining high proliferation while expanding cellular diversity in human small intestinal organoids. Its reversible and directional control of lineage output offers a practical framework for scalable organoid culture, although the system remains an in vitro model that requires context-specific validation.
-
TPPU: Practical sEH Inhibition Workflows
2026-09-16
TPPU is a nanomolar soluble epoxide hydrolase inhibitor for connecting fatty acid epoxide signaling with inflammatory pain, redox biology, and bone research. This workflow-focused guide covers formulation, lipid mediator assays, osteoclast experiments, controls, and troubleshooting for more reproducible sEH studies.
-
A1 CXCR4 Inhibition in Colorectal Cancer
2026-09-16
Khorramdelazad et al. evaluated the fluorinated CXCR4 inhibitor A1 across molecular modeling, CT-26 cell assays, and a murine colorectal cancer model, using AMD3100 as a comparator. A1 showed stronger predicted receptor binding, reduced tumor-cell proliferation and migration, altered immunosuppressive tumor-microenvironment signals, and improved tumor control and survival in vivo, although further validation is needed before clinical translation.
-
PLPP1, Z-Ligustilide, and Cisplatin Resistance
2026-09-15
This preprint links the activity of Z-ligustilide plus cisplatin to PLPP1-associated phospholipid remodeling, reduced PIP3–AKT signaling, cell-cycle arrest, and apoptosis in cisplatin-resistant lung cancer cells. Its integrated metabolomics, transcriptomics, functional knockdown, and clinical-dataset analyses suggest a mechanistic framework for studying lipid metabolism in cisplatin resistance, while the preclinical design requires validation beyond the tested cell models.
-
Gut Microbiota, RPE/Choroid, and AMD Transcriptomics
2026-09-15
Zhang and colleagues show that the absence of gut microbiota is associated with distinct RPE/choroid gene-expression changes and reduced laser-induced choroidal neovascularization in mice. The study provides experimental support for a gut–RPE/choroidal axis in AMD-related biology while also highlighting the need to distinguish microbiota-associated effects from model-specific and tissue-collection factors.
-
Bifendate Attenuates Hepatic Steatosis in Mice
2026-09-14
The reference study showed that Bifendate selectively reduced hepatic cholesterol and triglyceride accumulation in several mouse models of diet- and cholesterol-induced hypercholesterolemia. Its key contribution was to distinguish liver lipid lowering from systemic serum lipid reduction, providing a focused preclinical rationale for studying DDB as a hepatoprotection agent and lipid metabolism regulator.
-
Calcitriol B2141 for Reliable Cell Assays
2026-09-14
Learn how Calcitriol (SKU B2141), the active metabolite of vitamin D3, can support more interpretable proliferation, viability, differentiation, and immune-modulation experiments. This scenario-driven guide covers assay interpretation, solvent handling, endometrial models, cytokine studies, and practical vendor-selection criteria.
-
C8-HSL Drives Lung Cancer Cell Aggressiveness
2026-09-13
A 2026 FASEB Journal study identifies the bacterial quorum-sensing molecule C8-HSL as a potential mediator between lung microbiota and malignant behavior. Using H460 lung cancer models, the researchers linked C8-HSL exposure to increased proliferation, migration, and invasion through PI3K/AKT/ERK activation and associated changes in cell-cycle and epithelial–mesenchymal markers.